2315 — Biocytogen Pharmaceuticals Beijing Co Income Statement
0.000.00%
Last trade - 00:00- HK$3.89bn
- HK$4.05bn
- CNY716.91m
Annual income statement for Biocytogen Pharmaceuticals Beijing Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 254 | 355 | 534 | 717 |
| Cost of Revenue | ||||
| Gross Profit | 167 | 247 | 392 | 506 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 612 | 860 | 1,064 | 987 |
| Operating Profit | -358 | -506 | -530 | -270 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -477 | -546 | -601 | -380 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -477 | -546 | -602 | -383 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -428 | -546 | -602 | -383 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -428 | -546 | -602 | -383 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.12 | -1.4 | -1.63 | -0.988 |